|
|
|
|
| LEADER |
01335nam a2200253 u 4500 |
| 001 |
EB002191646 |
| 003 |
EBX01000000000000001329111 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 100 |
1 |
|
|a Subramonian, Anusree
|
| 245 |
0 |
0 |
|a Brivaracetam versus levetiracetam for epilepsy
|h Elektronische Ressource
|b a review of comparative clinical safety
|c Anusree Subramonian, Kelly Farrah
|
| 250 |
|
|
|a Version:1.0
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, December 1, 2020
|
| 300 |
|
|
|a 1 PDF file (35 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Farrah, Kelly
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK567269
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to summarize the evidence regarding the comparative clinical safety of BRV compared to LEV among patients with epilepsy with mental health conditions as well as in patients with epilepsy who experienced psychiatric or behavioral adverse events with previous LEV treatment
|